Latest Manufacturing Capacity News

Boresight Ltd (ASX: BST) marked its ASX debut in June with a successful $8 million IPO, reporting a 55% revenue increase in FY26 and securing a major US manufacturing expansion to meet rising defence drone demand.

IperionX reports steady ramp-up of titanium powder output at Virginia facility, successful commissioning of major powder metallurgy equipment, and progress in customer product development. The Titan DFS confirms strong project economics, while the Atlas acquisition broadens critical mineral resources and infrastructure.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

Aurora Labs marked its commercial debut by delivering AU4 micro gas turbine propulsion systems to Sovereign Propulsion Systems, while securing a $1 million government grant to scale production and formalising a strategic defence partnership with MBDA.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

DXN Limited has landed a $1.2 million contract for a key Pacific submarine cable project while advancing its maiden AI HPC modular data centre deal and expanding manufacturing in Southeast Asia.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

AML3D Limited closed FY26 with a record $29 million order book, driven by US defence contracts and a $12 million investment to double its Ohio manufacturing capacity. The company’s cash receipts rose 20% to $10.4 million, while its sales pipeline expanded to $78 million.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.